Skip to content
Back to meeting Original
Dr. Antonio Calles 馃珌馃毉路 @Tony_Calles 路 X路路 4 days agoScore45

lorlatinib

Body

馃К @bensolomon1 walked us through molecular insights of early progressions with lorlatinib in the CROWN trial including 馃└ @GuardantHealth Infinity assay #ESMO26 #LCSM

86 views 路 1 like 路 1 repost 路 0 replies

Conference abstracts
2636ROmatched by Rapid oral 1: NSCLC, metastatic

Characterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study

https://esmocongress.esmo.org

Source: Dr. Antonio Calles 馃珌馃毉 路 x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website鈥檚 feedback page.